Crowdfunding enables infant with rare genetic disorder to access gene therapy

A crowdfunding initiative has enabled a seven-month-old child diagnosed with spinal muscular atrophy (SMA) to access gene therapy treatment worth ₹10 crore, marking a significant milestone in the family's battle against the rare genetic disorder. SMA is a progressive condition that affects nerve cells responsible for controlling voluntary muscles, potentially limiting mobility and life expectancy without intervention. Gene therapy represents one of the most advanced treatment options available for the condition, though its prohibitive cost places it beyond reach for most families in India. The successful crowdfunding campaign demonstrates the growing role of community support in bridging the gap between cutting-edge medical treatments and affordability. Medical experts emphasize that early intervention with gene therapy can substantially improve outcomes for SMA patients, with treatment most effective when administered during infancy before significant muscle degeneration occurs. The case highlights the urgent need for expanded access to advanced genetic treatments in India and underscores the financial burden faced by families of children with rare diseases. Healthcare advocates have called for greater insurance coverage and government support mechanisms to ensure equitable access to such life-saving therapies across the country.